Leerink Swann Upgrades Caliper Life Sciences (CALP) to Outperform; Strength Should Continue
Tweet
Share
E-mailGet Alerts CALP Hot Sheet
Price: $10.49 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Leerink Swann upgraded Caliper Life Sciences (NASDAQ: CALP) from Market Perform to Outperform.
Leerink analyst says, "We are upgrading CALP to Outperform following strong 1Q results. We have recently become more bullish on CALP's opportunity in nextgen sequencing (NGS), and believe momentum in CALP's business could drive upside to 2011 expectations, which in turn could generate some multiple expansion. Our new valuation range is $8.50 to $9.50 (from $6.75 to $7.25)."
For more ratings news on Caliper Life Sciences click here and for the rating history of Caliper Life Sciences click here.
Shares of Caliper Life Sciences closed at $6.72 yesterday.
Leerink analyst says, "We are upgrading CALP to Outperform following strong 1Q results. We have recently become more bullish on CALP's opportunity in nextgen sequencing (NGS), and believe momentum in CALP's business could drive upside to 2011 expectations, which in turn could generate some multiple expansion. Our new valuation range is $8.50 to $9.50 (from $6.75 to $7.25)."
For more ratings news on Caliper Life Sciences click here and for the rating history of Caliper Life Sciences click here.
Shares of Caliper Life Sciences closed at $6.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Jefferies Upgrades Brightstar Lottery (BRSL) to Buy
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
